乐观
$117.84
情景价格
$92.030
-0.479 (-0.52%)收盘时
HealthEquity, Inc. is engaged in providing technology-enabled services that enables consumers to make healthcare saving and spending decisions. The Company uses its technology to manage consumer tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and to administer Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It provides consumers with payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice. It offers an investment platform and access to an online-only automated investment advisory service to all of its members whose account balances exceed a stated threshold. It administers pre-tax commuter benefit programs through which employers are permitted to provide employees with commuter benefits including qualified transit and parking.
HealthEquity Inc is a good buy right now due to its current price of $92.61, which is significantly below the average analyst price target of $115 to $142, indicating potential upside. Additionally, the company's forward P/E ratio is 19.72, suggesting it is reasonably valued for future growth. However, a key risk is the recent insider selling activity, which has increased by 213.73% over the last quarter, indicating potential concerns from insiders about future performance.
Barclays
$115
2026-09-18
Barclays
2026-09-18
目标价
$115
Deutsche Bank
$142
2026-08-31
Deutsche Bank
2026-08-31
目标价
$142
BTIG
$115
2026-07-24
BTIG
2026-07-24
目标价
$115
Citizens
$111
2026-06-01
Citizens
2026-06-01
目标价
$111
RBC Capital
$108
2026-05-29
RBC Capital
2026-05-29
目标价
$108
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

HealthEquity Reports Strong Q2 Earnings with Record Growth

HealthEquity Reports Strong Earnings but Faces Stock Sell-Off

HealthEquity Reports Strong Q2 Earnings but Stock Declines

Healthcare Stocks Decline 1.2% on NYSE

HealthEquity Announces Q2 Fiscal 2027 Earnings Release Plans
HealthEquity, Inc. is engaged in providing technology-enabled services that enables consumers to make healthcare saving and spending decisions. The Company uses its technology to manage consumer tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and to administer Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It provides consumers with payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice. It offers an investment platform and access to an online-only automated investment advisory service to all of its members whose account balances exceed a stated threshold. It administers pre-tax commuter benefit programs through which employers are permitted to provide employees with commuter benefits including qualified transit and parking. It operates in the Technology sector (SERVICES-BUSINESS SERVICES, NEC industry).
HealthEquity Inc is a good buy right now due to its current price of $92.61, which is significantly below the average analyst price target of $115 to $142, indicating potential upside. Additionally, the company's forward P/E ratio is 19.72, suggesting it is reasonably valued for future growth. However, a key risk is the recent insider selling activity, which has increased by 213.73% over the last quarter, indicating potential concerns from insiders about future performance.
10 analysts cover HQY: 9 rate it Buy, 1 Hold and 0 Sell. The average price target is 117.09.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。